174 related articles for article (PubMed ID: 9927581)
1. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection.
Mozdzanowska K; Maiese K; Furchner M; Gerhard W
Virology; 1999 Feb; 254(1):138-46. PubMed ID: 9927581
[TBL] [Abstract][Full Text] [Related]
2. Immunization with dissociated neuraminidase, matrix, and nucleoproteins from influenza A virus eliminates cognate help and antigenic competition.
Johansson BE; Kilbourne ED
Virology; 1996 Nov; 225(1):136-44. PubMed ID: 8918540
[TBL] [Abstract][Full Text] [Related]
3. Virus-neutralizing activity mediated by the Fab fragment of a hemagglutinin-specific antibody is sufficient for the resolution of influenza virus infection in SCID mice.
Mozdzanowska K; Feng J; Gerhard W
J Virol; 2003 Aug; 77(15):8322-8. PubMed ID: 12857901
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components.
Mozdzanowska K; Feng J; Eid M; Zharikova D; Gerhard W
Virology; 2006 Sep; 352(2):418-26. PubMed ID: 16777168
[TBL] [Abstract][Full Text] [Related]
5. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.
Chen Y; Qin K; Wu WL; Li G; Zhang J; Du H; Ng MH; Shih JW; Peiris JS; Guan Y; Chen H; Xia N
J Infect Dis; 2009 Jan; 199(1):49-58. PubMed ID: 19032063
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein.
Wang R; Song A; Levin J; Dennis D; Zhang NJ; Yoshida H; Koriazova L; Madura L; Shapiro L; Matsumoto A; Yoshida H; Mikayama T; Kubo RT; Sarawar S; Cheroutre H; Kato S
Antiviral Res; 2008 Nov; 80(2):168-77. PubMed ID: 18598723
[TBL] [Abstract][Full Text] [Related]
7. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro.
Mozdzanowska K; Furchner M; Washko G; Mozdzanowski J; Gerhard W
J Virol; 1997 Jun; 71(6):4347-55. PubMed ID: 9151823
[TBL] [Abstract][Full Text] [Related]
8. Fine specificity and sequence of antibodies directed against the ectodomain of matrix protein 2 of influenza A virus.
Zhang M; Zharikova D; Mozdzanowska K; Otvos L; Gerhard W
Mol Immunol; 2006 Jul; 43(14):2195-206. PubMed ID: 16472860
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.
Tamura S; Tanimoto T; Kurata T
Jpn J Infect Dis; 2005 Aug; 58(4):195-207. PubMed ID: 16116250
[TBL] [Abstract][Full Text] [Related]
10. A humanized anti-M2 scFv shows protective in vitro activity against influenza.
Gabbard J; Velappan N; Di Niro R; Schmidt J; Jones CA; Tompkins SM; Bradbury AR
Protein Eng Des Sel; 2009 Mar; 22(3):189-98. PubMed ID: 19054791
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a fully human monoclonal antibody against multiple influenza A viral strains in mice and a pandemic H1N1 strain in nonhuman primates.
Song A; Myojo K; Laudenslager J; Harada D; Miura T; Suzuki K; Kuni-Kamochi R; Soloff R; Ohgami K; Kanda Y
Antiviral Res; 2014 Nov; 111():60-8. PubMed ID: 25218949
[TBL] [Abstract][Full Text] [Related]
12. Interaction of hydrophobized antiviral antibodies with influenza virus infected MDCK cells.
Melik-Nubarov NS; Suzdaltseva YuG ; Priss EL; Slepnev VI; Kabanov AV; Zhirnov OP; Sveshnikov PG; Severin ES
Biochem Mol Biol Int; 1993 Apr; 29(5):939-47. PubMed ID: 8508145
[TBL] [Abstract][Full Text] [Related]
13. [Role of antineuraminidase antibodies in protection against influenza].
Aymard M; Gerentes L; Kessler N
Bull Acad Natl Med; 1998; 182(8):1723-36; discussion 1736-7. PubMed ID: 10188318
[TBL] [Abstract][Full Text] [Related]
14. Variation in response among individuals to antigenic sites on the HA protein of human influenza virus may be responsible for the emergence of drift strains in the human population.
Nakajima S; Nobusawa E; Nakajima K
Virology; 2000 Aug; 274(1):220-31. PubMed ID: 10936103
[TBL] [Abstract][Full Text] [Related]
15. Local IL-4 expression in the lung reduces pulmonary influenza-virus-specific secondary cytotoxic T cell responses.
Bot A; Holz A; Christen U; Wolfe T; Temann A; Flavell R; von Herrath M
Virology; 2000 Mar; 269(1):66-77. PubMed ID: 10725199
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge.
Liu W; Zou P; Chen YH
Immunol Lett; 2004 May; 93(2-3):131-6. PubMed ID: 15158608
[TBL] [Abstract][Full Text] [Related]
17. Different neutralization efficiency of neutralizing monoclonal antibodies against avian influenza H5N1 virus to virus strains from different hosts.
Huang H; Dan H; Zhou Y; Yu Z; Fan H; Tong T; Jin M; Chen H
Mol Immunol; 2007 Feb; 44(5):1052-5. PubMed ID: 16965815
[TBL] [Abstract][Full Text] [Related]
18. [Various sides of influenza, part I--structure, replication, changeability of influenza viruses, clinical course of the disease, immunological response and laboratory diagnostics].
Machała MK; Brydak LB
Pol Merkur Lekarski; 2006 Sep; 21(123):270-6. PubMed ID: 17163190
[TBL] [Abstract][Full Text] [Related]
19. [Antiviral effect of recombinant antibody to influenza virus HA antigen].
Yang G; Wang Y; Zhao X; Han F; Wu S; Hou Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Dec; 16(4):337-40. PubMed ID: 12665899
[TBL] [Abstract][Full Text] [Related]
20. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.
Feng JQ; Mozdzanowska K; Gerhard W
J Virol; 2002 Feb; 76(3):1369-78. PubMed ID: 11773411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
